• Array

    Who we are

Executive Board

Professor Dr. Martin F. Bachmann (CSO and co-founder HypoPet AG)
Martin Bachmann, Professor at the Universities of Bern and Oxford is a pioneer and world leader in VLP-based vaccines who possesses a unique combination of academic excellence, industry acumen and entrepreneurship. Martin received his PhD from the Institute for Experimental Immunology, Zurich, in the laboratory of Nobel Laureate Prof. Dr. Rolf Zinkernagel. He has more than 20 years of experience in drug research and development and has established a vast and renowned network of industrial and academic partners. He is the founder of Saiba GmbH and formerly worked for Cytos Biotechnology AG as CSO. One of his projects that was co-developed with Novartis is currently being tested in a late phase clinical registration study involving 690 patients. Martin has more than 250 peer reviewed publications and is listed as an inventor on more than 50 patents.

Professor Dr. Thomas M. Kündig (CMO and co-founder HypoPet AG)
Thomas completed his medical studies at the University of Zurich in 1987. After a two year post-graduate course in Experimental Medicine and Biology, he became a post-doctoral student at the Institute of Experimental Immunology in the laboratory of Nobel Laureate Prof. Dr. Rolf Zinkernagel. This was followed by another post-doctorate position at the Institute for Medical Biophysics at the University of Toronto. Since 1995 he has been working at the Dermatology Department of the University Hospital of Zurich. Thomas received his FMH in Dermatology 2002 and further specialized in Allergology and Clinical Immunology. Since 2006 he has been Head of Research at the Dermatology Department and since 2016 he has also been Head of the Policlinic and became a member of the Dermatology Clinic Management. Thomas received several awards, including the Venia Legendi of the University Zurich in the field of «Experimental Immunology» in 1998 and the Georg-Friedrich Götz Prize in 1999.

Dr. Gary T. Jennings (CEO/COO HypoPet AG)
Gary graduated as Doctor of Biochemistry (Ph.D.) from the University of Western Australia and completed post-doctoral appointments at the U.S. National Institutes of Health and the University of Texas. He gathered experience in the biotechnology and pharmaceutical industries over 20 years. During this time he worked in numerous roles and gained extensive experience in the R&D process including discovery research, safety testing, manufacturing, regulatory, clinical trials, project management, patenting and BD&L. Prior to joining HypoPet he held senior positions with Novartis, Cytos Biotechnology and Chiron Corporation.

Patrik M. Paulus (Executive Chairman, interim CFO and co-founder HypoPet AG)
Patrik studied Business Administration & Tax Law in Germany. He has more than 25 years of experience in Banking and Management, ten of which were as CEO of Liechtensteinische Landesbank (Schweiz) AG. He is currently enjoying success as an Entrepreneur and Co-Founder of several Startups and is Founder & Chairman of FIO Partners AG, Multi Family Office. Patrik boasts a vast knowledge of Financial and Capital Markets. By assuming the company‘s Finance authority, Patrik brings the financial skills and know-how to the firm‘s team of scientists

Board of directors

In addition to Martin F. Bachmann, Thomas M. Kündig and Patrik Paulus the competence power of Gabriela Senti and Thomas Klein completes the Board of directors.

Professor Dr. med. Gabriela Senti (co-founder HypoPet AG)
Gabriela Senti is the Director of Research and Education of the University Hospital Zurich and is heading the Clinical Trials Center at the Center for Clinical Research of the University and University Hospital Zurich. Gabriela studied medicine at the University Zurich. Her FMH specializations are Dermatology and Venereology, Allergology and Clinical Immunology and, Pharmaceutical Medicine. In 2009 she achieved the Venia Legendi in Pharmaceutical Medicine in the field of Translational Research “Developing New Methods for Allergen Specific Immunotherapy”. She is a member of the board of the Swiss Association of Pharmaceutical Medicine, IG Immunotherapy at the European Academy of Allergy and Clinical Immunology EAACI and founding president and current chairperson of the International Network of Clinical Trial Centers ICN.

Thomas Klein, Attorney at Law
Thomas Klein was admitted to the bar in 1985 in Switzerland after his studies at the Universities of Basel and Geneva. He has gained experienced in a Swiss bank and in an international law firm in Zurich. Today he is leading with his partners the law firm Klein Attorneys AG in Zurich, which have their expertise in selected business sectors including pharmaceuticals and life sciences.

Development Team

Dr. Senta Walton
Senta Walton has over 9 years of experience in the biotechnology sector and joined HypoPet in 2019 as Head of Research and Development. Her roles at HypoPet include project management, regulatory affairs, product development, preclinical and clinical research. Senta holds a PhD in biology from the Federal Institute of Technology in Zurich, Switzerland and has considerable research experience in the field of immunology particularly in the context of chronic immunopathology. She previously worked as the Head of Immunology at Ondek Australia developing an immunotherapy for the pediatric market.

Dr. med. vet. Lino Camponovo
Lino is a development and marketing adviser for HypoPet. His previous experience includes General Manager at Zoetis Schweiz GmbH, Co-Founder and Chief Executive Officer of Malcisbo AG, Chairman and Chief Executive Officer of Intervet India Pvt. Ltd. and, General manager of Veterinaria AG.